Eli Lilly and Company
Eli Lilly and Company Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
3 of 4 strong
The short version
- Full-year 2026 revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, reflecting strong momentum from Mounjaro and Semaglutide (SEB) (Page 4). - Full year revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, representing 28% growth vs.
From Eli Lilly and Company's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Full-year 2026 revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, reflecting strong momentum from Mounjaro and Semaglutide (SEB) (Page 4).
- Midpoint represents 28% growth compared to 2025 (Page 4).
- Continued volume-driven growth expected, fueled by expanding access and new patient starts, especially in obesity and type 2 diabetes markets (Page 7).
- Foundayo's early launch indicators positive; over 20,000 patients treated with 80% new-to-class prescriptions, with further growth driven by continued promotion and expanding payer access, including Medicare from July 2026 (Pages 10-11, 15).
- International markets showing rapid uptake; fully launched in over 55 countries with strong share gains despite generic competition (Page 7).
2 more points from Eli Lilly and Company's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Eli Lilly and Company said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Lilly continues to invest heavily in pipeline development, with 42 active Phase III programs.
- Increased R&D expenses by 28% in Q1 2026 to support ongoing and new product launches.
- Executed multiple acquisitions to expand capabilities and pipeline:
- Orna Therapeutics (in vivo CAR T for autoimmune diseases)
- Sytesa Pharmaceuticals (orexin receptor 2 agonists for sleep disorders)
- Colonia Therapeutics (lentiviral in vivo CAR T for multiple myeloma)
- Ajax Therapeutics (next-gen JAK inhibitors for blood cancers)
- Contessa Pharmaceuticals (expands neuroscience portfolio)
- Launched Lilly Employer Connect, a platform to engage employers in offering obesity medications.
- Committed to business development while maintaining shareholder value discipline.
2 more points from Eli Lilly and Company's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Eli Lilly and Company said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The upcoming Community Update Day is scheduled for Monday, December 7, with location and exact timing to be announced.
- Early launch metrics for Foundayo show over 20,000 patients treated to date, with 80% of prescriptions new to class.
- Commercial access for Foundayo confirmed at 2 of the large PBMs as of mid-May; Medicare access set to start in July.
- Employer Connect program has positive conversations with employers but impacts on coverage likely gradual, with more opt-ins expected in 2027.
2 more points from Eli Lilly and Company's call on order book
Create a free account to keep reading this call
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Eli Lilly and Company and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Eli Lilly and Company Q2 FY26 results?
- Full-year 2026 revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, reflecting strong momentum from Mounjaro and Semaglutide (SEB) (Page 4). - Full year revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, representing 28% growth vs.
What is Eli Lilly and Company share price analysis?
Eli Lilly and Company currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 37.9 with a market cap of $1,061,154. Investors should review the full earnings analysis for detailed insights.
Is Eli Lilly and Company planning capital expenditure?
- Lilly continues to invest heavily in pipeline development, with 42 active Phase III programs.
Keep Eli Lilly and Company on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.